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Abstract
Transplantation of mesenchymal stem cells (MSCs) derived from adult bone marrow has been proposed as a potential therapeutic
approach for post-infarction left ventricular (LV) dysfunction. However, age-related functional decline of stem cells has restricted their
clinical benefits after transplantation into the infarcted myocardium. The limitations imposed on patient cells could be addressed by
genetic modification of stem cells. This study was designed to improve our understanding of genetic modification of human bone mar-
row derived mesenchymal stem cells (hMSCs) by polyethylenimine (PEI, branched with Mw 25 kD), one of non-viral vectors that show
promise in stem cell genetic modification, in the context of cardiac regeneration for patients. We optimized the PEI-mediated reporter
gene transfection into hMSCs, evaluated whether transfection efficiency is associated with gender or age of the cell donors, analysed
the influence of cell cycle on transfection and investigated the transfer of therapeutic vascular endothelial growth factor gene (VEGF).
hMSCs were isolated from patients with cardiovascular disease aged from 41 to 85 years. Optimization of gene delivery to hMSCs was
carried out based on the particle size of the PEI/DNA complexes, N/P ratio of complexes, DNA dosage and cell viability. The highest effi-
ciency with the cell viability near 60% was achieved at N/P ratio 2 and 6.0 g DNA/cm2. The average transfection efficiency for all tested
samples, middle-age group (65 years), old-age group (65 years), female group and male group was 4.32%, 3.85%, 4.52%, 4.14%
and 4.38%, respectively. The transfection efficiency did not show any correlation either with the age or the gender of the donors.
Statistically, there were two subpopulations in the donors; and transfection efficiency in each subpopulation was linearly related to the
cell percentage in S phase. No significant phenotypic differences were observed between these two subpopulations. Furthermore, PEI-
mediated therapeutic gene VEGF transfer could significantly enhance the expression level.
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Introduction
Transplantation of mesenchymal stem cells (MSCs) derived from
adult bone marrow has been proposed as a potential therapeutic
approach for post-infarction left ventricular (LV) dysfunction.
MSCs can protect cardiomyocytes by expressing genes encoding
factors that are matrix-mediating, anti-apoptotic and angio-/arteri-
ogenic, as interleukin (IL)-6, leukaemia inhibitory factor (LIF) and
vascular endothelial growth factor (VEGF) family [1], prompt
angiogenesis in injured area by secreting angiogenetic and vascu-
logenetic products, particularly VEGF, hepatocyte growth factors,
adrenomedullin, placental growth factor and IL-6 [1]. MSCs 
were found to incorporate into vascular vessel walls of growing
neovasculature during cardiac tissue regeneration [2] and to
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transmigrate over the endothelial barrier of capillaries, disrupting
tight junctions between endothelial cells and developing tight
cell–cell contacts with the endothelial cells on its way [3]. Li et al.
[4] transplanted Bcl-2 modified MSCs into the infarcted heart in a
rat model and found that some of the MSCs appeared to display
endothelial cell-like phenotype. They also confirmed that a very
few number of MSCs colocalized with cardiac Troponin T (cTnT)
by the 3D reconstruction of the tissue acquired by a confocal
microscopy, suggesting the fusion of the transplanted MSCs with
host cells or the differentiation of the transplanted cells into car-
diomyocytes. Intramyocardial transplantation of MSCs led to ini-
tial enhancement of coronary blood flow and subsequent improve-
ment of cardiac performance 8 weeks after transient cardiac
ischemia in pigs [5]. Clinical studies revealed a reduction of per-
fusion defect along with improved overall LV function after intra-
coronary autologous MSCs administration [6].
However, the beneficial effect regarding functional recovery
after ischemia in patients was much less effective than predicted
by preclinical studies. Notably, most preclinical studies were
performed on healthy young animals, whereas most patients
enrolled in clinical trials were older patients with multiple 
comorbidities [7].
Diminished stem cell functions with age have been extensively
documented in previous studies [8–14]. Aging leads to a reduction
of telomere length of bone marrow derived cells especially in
patients with cardiovascular diseases [15–17], reduces cell survival
to ischemic injury, incurs less stem cell release of VEGF and basic
fibroblast growth factor (bFGF) in response to ischemia [7].
Fortunately the aging-related decline in cardiac and vascular regen-
erative capacity of stem cells could be addressed by pre-activation
of donor cells with genetic modification before implantation.
Indeed, genetic manipulation of rat MSCs with prosurvival kinase
Akt [18], anti-apoptotic Bcl-2 [4] and genetic modification of EPCs
with human telomerase reverse transcriptase [19], and VEGF [20]
have induced an increase in stem cell survival, enhanced regenera-
tive properties of stem cells in neovascularization and shown func-
tional improvement in disease models.
However, multiple issues have to be addressed before this
technology can be used in patients. In that silencing of virally
encoded genes in cells is not always complete. It is highly essen-
tial to identify alternative genetic modification techniques such as
non-viral vector gene transfer for delivering therapeutic genes into
the hMSCs without integrating viruses, thereby lowering the risk
of malignant transformation [21, 22]. Actually, genetic engineering
of human stem cells with VEGF by biodegradable polymeric
nanoparticles showed enhanced angiogenesis in a mouse
ischemic hindlimb model [23].
In this study, we used the polyethylenimine (PEI; 25 kD), a
widely used non-viral gene carrier with high delivery efficiency [22,
24–27], to deliver the gene into the bone marrow derived human
mesenchymal stem cells (hMSCs). The aim was to optimize the
transfection conditions, study the feasibility of non-viral gene deliv-
ery into hMSCs derived from patients and evaluate whether trans-
fection efficiency is associated with gender or age of the cell
donors. Here, we showed that there was no correlation between the
transfection efficiency and the age or gender of the donors; the
most interesting finding was that statistically there were two sub-
populations in the donors; and the transfection efficiency in each
subpopulation was linearly related to the cell percentage in S phase.
There were no significant phenotypic differences between these two
subpopulations. Furthermore, PEI-mediated therapeutic gene VEGF
transfer could significantly enhance the expression level.
Materials and methods
Chemicals and reagents
Branched PEI with weight average molecular weights (Mw) of 25,000
Dalton, MTT (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium
bromide) and ethidium bromide were purchased from Sigma-Aldrich (St.
Louis, MO, USA). Dimethyl sulphoxide (DMSO) with high purity (99.5%)
was purchased from Carl Roth (Karlsruhe, Germany). Ficoll-Paque PLUS
was purchased from GE Healthcare (Chalfont St. Giles, HP8 4SP, UK).
Amplification and purification of plasmid DNA
Plasmid enhanced green fluorescent protein (pEGFP-N3) (Clonetech, Palo
Alto, CA, USA) and pcEP4-VEGF165 (Invitrogen, Carlsbad, CA, USA) were
transformed into Escherichia coli DH5 strain and amplified in lysogeny
broth (LB) medium at 37C by shaking overnight at 200 rpm. Purification
and isolation of the amplified plasmid was carried out with plasmid DNA
purification kit (Macherey-Nagel, Diiren, Germany) according to the given
protocol. The concentration and purity of the plasmid were determined by
measuring the ultraviolet (UV) absorbance at 260 and 280 nm with a spec-
trophotometer (Thermo Electron, Waltham, MA, USA). Finally, the purified
plasmid was stored in aliquots at 	20C prior to use.
PEI/DNA complexes preparation 
and characterization
The PEI/DNA complexes were prepared as we described previously [22,
28, 29]. Plasmid DNA was diluted to 
0.1 mg/ml with 5% glucose. Then,
PEI with appropriate concentration (normally 
0.75 mM primary amine)
in 5% glucose was added drop-wise into DNA solution and the mixture was
immediately vortexed for 30 sec. and incubated at room temperature for 
30 min. The ratio of PEI nitrogen in primary amine/DNA phosphate (N/P ratio)
was calculated by taking into account that 1 g DNA contains 3 nmol 
of phosphate and that 43 ng PEI (1 nmol of C2H5N repeat units) holds 
0.25 nmol of primary amine nitrogen.
The retardation of DNA by PEI was studied by gel electrophoresis.
PEI/DNA complexes mixed with loading buffer was loaded onto the 
ethidium bromide containing gel (1.5% agarose) and the electrophoretic
mobility of the sample was measured at 100 V in tris/borate/ethylenedi-
aminetetraacetic acid (TBE) buffer at room temperature. The DNA bands
were visualized under an UV illuminator (Gel Doc 2000 system, Bio-Rad,
Hercules, CA, USA). PEI/DNA complex size and  potential were measured
with ZetaPALS analyser (Brookhaven Instruments Corporation, Holtsville,
NY, USA) at 25C by diluting the complex solution with 5% glucose to the
final DNA concentration of 0.025 mg/ml for characterization.
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hMSCs isolation, culture and characterization
The study conforms to the Declaration of Helsinki and cell donors gave their
informed written consent to use their bone marrow for experimental pur-
poses. hMSCs were isolated from bone marrow samples. Firstly, bone mar-
row samples were diluted with serum-free Roswell Park Memorial Institute
(RPMI)1640 medium (PAA Laboratories, Coelbe, Germany) and shook 
30 min. at room temperature for complete mixing. Then, the mixtures were
filtered with 30 M cell strainer to remove the clusters, layered on Ficoll-
Paque PLUS and centrifuged at 1000  g for 10 min. at room temperature.
The separated monocytes layer above Ficoll after centrifugation was care-
fully collected and washed three times with 1 PBS/EDTA [phosphate-
buffered solution/ethylenediaminetetraacetic acid (2 mM)]. Finally, the cells
were resuspended in MSC growth medium (Lonza, Walkersville, MD, USA)
and cultured in a humidified atmosphere of 5% CO2 in air at 37C. The
growth medium was changed regularly during the culture.
hMSCs were analysed for purity and epitope expression using fluores-
cence-activated cell sorter (FACS) analysis. The cells were blocked with
FcR Blocking Reagent (human) (Miltenyi Biotec, Bergisch Gladbach,
Germany) and incubated for 30 min. at 4C with corresponding antibodies:
CD29, CD44, CD45, CD73 (BD Biosciences, Heidelberg, Germany) and
CD105 (AbD Serotec, Düsseldorf, Germany). Suggested mouse isotype
antibodies were used as control. After incubation, the cells were washed
with 1  PBS/EDTA (2 mM) and analysed using a LSR II Flow Cytometer
(Becton Dickinson, Heidelberg, Germany). Dead cells were excluded using
dead cell stain kit (LIVE/DEAD®, Invitrogen). Data analysis was performed
with BD FACSDivaTM software (BD Biosciences). Histograms of cell num-
ber versus logarithmic fluorescence intensity were recorded for at least
10,000 cells per sample. The cell morphology was observed under micro-
scope (Axiovert40 CFL, Carl Zeiss, Goettingen, Germany).
MTT cytotoxicity assay
hMSCs were seeded into the 96-well plates with the density of 4.27  103
cells/well. After 40 hrs of culture at 37C, 20 l MTT (5 mg/ml in 1 PBS)
was added into every well. After 4 hrs of incubation at 37C, the medium
was removed and the purple crystals were dissolved in 100 l DMSO. The
absorbance was measured at a test wavelength of 550 nm and a reference
wavelength of 655 nm using a microplate reader (Bio-Rad, Model 680).
The results were expressed as the percentage of viability compared with
control cells, which were cultured without complex treatment. Cell viability
was calculated using the equation below:
Cells viability (%)  (OD550 – OD655, samples/OD550 – OD655, control)  100%
In vitro transfection
For the optimization of the transfection conditions, hMSCs were seeded
into 6-well plates at the density of 4.18  104 cells/per well. The medium
volume for every plate was 5 ml. After 24 hrs of culture, the PEI/DNA com-
plexes were added into the cell culture medium. After 24 hrs of transfec-
tion, the cells were observed by fluorescence microscopy and the transfec-
tion efficiency was analysed with FACSCaliburTM flow cytometer (Becton
Dickinson). Briefly, the culture medium was removed and the cells were
washed three times by 1 PBS. Then, the cells were harvested by incubat-
ing with trypsin-EDTA and washed twice with 1 PBS. For every FACS-
running at least 10,000 cells were counted. The untransfected cells from
the same donors were used as control. The data were analysed with
‘FlowJo’ software and the gate for control was set as 
1%. After that, all
of the hMSCs from different resources were transfected using the optimal
conditions with the same protocol.
Cell cycle analysis
The cell cycle analysis was performed to investigate the effect of cell cycle
especially S phase on the transfection efficiency. The cells were stained
with propidium iodide (PI) according to the standard protocol followed by
the FACS detection. The data were analysed using the ‘Cell Cycle’ platform
of the ‘FlowJo’ software.
Human VEGF165 transfection
hMSCs from eight patients were transfected with effector gene (human
VEGF165). The cells from each patient were divided into 3 groups: nega-
tive control (without any treatment), naked plasmid (6 g VEGF165/cm2)
transfected group and PEI/DNA (N/P ratio 2, 6 g VEGF165/cm2) trans-
fected group. Cells were pre-seeded in 24-well plates. The medium was
replaced with fresh medium (1 ml/well) before transfection. After 24 hrs of
transfection, the culture medium was collected and stored at 	20C. The
VEGF protein content in the culture medium was quantified using a human
VEGF ELISA kit (QuantiGlo, R&D Systems, Wiesbaden-Nordenstadt,
Germany) following the given manual. The total protein level in the cell
extracts was measured with a BCA protein assay kit (Thermo Fisher
Scientific, Bonn, Germany) and was used as reference.
Statistical analysis
Statistical analysis was performed with the statistic program package
SPSS Version 15.0. A significance level (Sig.) 0.05 was considered to be
statistically significant.
Results
PEI/DNA complexes characterization
DNA immobilization by PEI was studied by electrophoresis. As
shown in Figure 1A, with the increase of N/P ratio, the DNA retar-
dation increased. At the absence of PEI (N/P ratio  0), the naked
DNA showed a broad and bright band under the UV illuminator.
However, with the gradually increased N/P ratio, the DNA band
became narrower and weaker. Finally, the DNA band disappeared
at N/P ratio 1 indicating that the DNA was completely retarded.
The size and surface charge of complexes are important 
factors which affect the transfection efficiency [30]. Figure 1B
indicated the decreasing trend of complex size and the increasing
trend of surface charge with the increase of N/P ratio. The average
complex size was 211.6 nm at N/P ratio 0.5 and significantly
decreased to 93.9 nm at N/P ratio 4. After that, the complex size
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became close to constant from N/P ratio 6 (80.9 nm) to N/P ratio
12 (70.6 nm).  Correspondingly, the average  potential increased
from 	9.61 mV to 41.03 mV with the increase of N/P ratio from
0.5 to 4. After that, it increased gently from N/P ratio 6 (43.07 mV)
to N/P ratio 12 (45.35 mV).
hMSCs characterization
The immunophenotyping of cell surface antigens was examined
by flow cytometry. As shown in Figure 2A, the cells showed posi-
tive expression of MSC markers CD29, CD44, CD73, CD105, and
negative expression of haematopoietic stem cell markers CD45.
Although there were some differences in the morphology of the
cells isolated from different donors, the cells displayed a homog-
enous elongated spindle-shaped population and maintained a sim-
ilar shape during the subsequent passages (Fig. 2B).
MTT cytotoxicity assay
The cytotoxicity induced by PEI/DNA complexes was studied by
MTT assay (Fig. 3). Both of N/P ratio and DNA dosage were var-
ied. The cell viability decreased with the increase of the complex
dosage when the N/P ratio was fixed. At lower N/P ratio,
PEI/DNA complexes did not show high toxicity even though 
the DNA dosage was relatively large. The cell viability exceeded
100% at N/P ratio 1 and DNA dosage of 7 g DNA/cm2. When
the N/P ratio increased to 2, it still kept more than 50% even 
at high DNA dosage (58.95  10.24% at 6 g DNA/cm2 and
59.82  6.95% at 7 g DNA/cm2). However, when the N/P ratio
exceeded 2, cell viability with more than 50% could be achieved
only at lower DNA dosage (0.5 or 1 g DNA/cm2). On the 
other side, if the DNA dosage was fixed, the cell viability showed
the decreasing trend with the increase of N/P ratio. Summarily,
the cell viability was affected by both of the N/P ratio and 
DNA dosage.
In vitro transfection optimization
To optimize the transfection conditions, three hMSC samples were
used for gene delivery assay with various N/P ratio and DNA
dosage. The representative results from FACS analysis (Fig. 4A)
showed that both N/P ratio and DNA dosage could influence the
gene delivery efficiency. At N/P ratio 1, although the efficiency
increased with the increase of DNA dosage, it was still very low
even at high DNA dosage (5.98% at 8.0 g DNA/cm2). When the
N/P ratio increased to 2, the efficiency was enhanced and showed
a maximum peak (24.24%) at 6.0 g DNA/cm2. After that, the effi-
ciency showed a decreasing trend with the increase of N/P ratio.
The FACS analysis histograms at N/P ratio 2 with various DNA
dosages are shown in Figure 4B. The green fluorescent protein
(GFP) expression of transfected cells at the optimal conditions are
shown in Figure 4C–E. Hence, all of the transfection were carried
out with the optimal conditions, i.e. N/P ratio 2 and 6.0 g
DNA/cm2, in the following experiments.
Effect of cell resource on transfection efficiency
Figure 5A revealed the effect of cell resource on transfection. The
cells used were from 30 donors, including 23 male and 7 female.
The average age of these donors was 67.6 years old and the 
average transfection efficiency was 4.32%. The Spearman’s rank
correlation coefficient (rs) between transfection efficiency and
donors’ age was not significant (rs (GFP: Age)  0.042, Sig. 
0.824), which indicated that the transfection efficiency was not
correlated with donors’ age. Furthermore, to evaluate the transfec-
tion efficiency difference between middle- and old-age people, we
divided the donors into two groups. Independent-samples t-test
revealed there was no significant transfection efficiency difference
(Sig.  0.634) between the under 65 years old group (n 9, aver-
age age  55.2 years, average GFP  3.85%) and over 65 years
old group  (n  21, average age  72.9 years, average GFP 
4.52%), as shown in Figure 5B. Moreover, we did not find the sig-
nificant transfection efficiency difference (Sig.  0.874) between
the female (n  7, average age  66.7 years, average GFP 
4.14%) and male (n  23, average age  67.8 years, average
GFP  4.38%) groups via independent-samples t-test (Fig. 5C).
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Fig. 1 Characterization of PEI/DNA complexes. Plasmid DNA was increas-
ingly retarded by PEI with the increase of N/P ratio, until the complete
retardation at N/P ratio 1 (A). PEI/DNA complex size was reduced, whereas
 potential was increased with the increase of N/P ratio from 0.5 to 12 (B).
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Effect of S phase on transfection efficiency
Previous works have revealed that the cells in S phase achieved
significant higher transfection efficiency than the cells in G1
phase [31, 32]. The effect of S phase on the transfection 
efficiency was investigated in this study (Fig. 6A). Interestingly
statistic analysis found that there were two subpopulations in
donors; in each of these two subpopulations transfection efficiency
was linearly related to the cell percentage in S phase. Pearson
correlation coefficient between transfection efficiency and the cell
percentage in S phase (Pearson r) was analysed, which was
0.969 for subpopulation 1 (P1) (n  6, Sig.  0.01) and 0.822
for subpopulation 2 (P2) (n 6, Sig.  0.05). Furthermore, non-
parametric Mann-Whitney test revealed that the GFP percent-
ages of P1 and P2 were from two different distributions (Asymp.
Sig.  0.01); but the cell percentages in S phase of P1 and P2
were not (Asymp. Sig.  0.10). A representative histogram of cell
cycle analysis via PI staining and FACS detection is shown in 
Figure 6B. In addition, phenotypic characterization was per-
formed with cells of these two subpopulations and there was no
significant difference observed on the surface markers: CD29,
CD44, CD45, CD73 and CD105 (Fig. 6C).
Human VEGF165 Transfection
To investigate whether PEI could mediate the delivery of therapeutic
gene into hMSC, the cells were transfected with human VEGF165
gene (Fig. 7). Both naked plasmid DNA and PEI/DNA complex led to
a significant expression of VEGF165 compared with untransfected
cells. However, the utilization of PEI resulted in a significant higher
transgene expression than naked plasmid DNA.
Similar to the transfer of GFP reporter gene, the VEGF165
transfection mediated by PEI presented large variation of effi-
ciency in cells from different patients. Among the eight patients,
the highest VEGF165 expression was 5.79 pg/g total cell protein,
which showed 4.54-fold enhancement compared to untransfected
cells (donor age 70, male); whereas the lowest VEGF165 expression
was 1.86 pg/g total cell protein, which only showed 1.18-fold
enhancement compared to untransfected cells (donor age 73,
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Fig. 2 Representative result of the phenotypic
characterization of hMSCs (A). The cells showed
positive expression of MSC markers CD29, CD44,
CD73, CD105 and negative expression of
haematopoietic stem cell markers CD45. The
hMSCs had a spindle-shaped morphology (B)
(Bar  100 M).
Fig. 3 The cell viability decreased with the increase
of N/P ratio and/or DNA dosage. The result was
given as average  S.D. (n  8).
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female). Further calculation based on cell number showed 
that VEGF expression levels ranged from 35 ng/106 cells/day to
230 ng/106 cells/day.
Discussion
The current study optimized the PEI-mediated reporter gene trans-
fection into hMSCs derived from patients based on the particle size
of the PEI/DNA complexes, N/P ratio of complexes, DNA dosage
and cell viability, and investigated the influence of cell cycle on
transfection. The transfection efficiency did not show any correla-
tion either with the age or the gender of the donors. Statistically,
there were two subpopulations in the donors; and transfection 
efficiency in each subpopulation was linearly related to the cell 
percentage in S phase. No significant phenotypic differences were
observed between these two subpopulations. Furthermore, the 
PEI-mediated transfer of therapeutic gene VEGF could significantly
enhance the expression level.
We tried to determine whether the transfection efficiency in
hMSCs is related to the donors’ age or gender. No statistical 
significance was observed showing that the transfection efficiency
did not have any correlation either with the age or the gender of
the donors. Also the individual differences in the transfection 
efficiency were relatively large. The most evident contrast came
from the two samples, which were from the donors with the same
age (67 years old) and gender (male). The transfection efficiencies
of these two samples were 16.55% and 6.17%, respectively. It is
not clear which specific differences in donors lead to the individual
difference in the transfection of hMSCs. Further studies are clearly
needed to study the inherent differences from the patients, which
induce the individual difference in the transfection of hMSCs.
Brunner et al. [31] used TfPEI (a conjugate with molar ratio of
approximately three transferring molecules linked to PEI800 Da) to
mediate GFP reporter gene expression in K562 cells. They also used
branched PEI25 kD and a small amount of TfPEI25 kD (human
transferrin coupled to branched PEI25 kD, representing 5% 
of the total PEI used for complex formation) to investigate 
the luciferase reporter gene expression in HeLa cells [32]. Both
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Fig. 4 Representative transfection efficiencies of hMSCs (donor age 67, male) with various N/P ratio and DNA dosage (A), and the histograms of FACS
analysis at N/P ratio 2 and various DNA dosage (B). (C–E): Representative GFP expression of transfected hMSCs under optimal transfection conditions.
Fluorescence image (C), phase-contrast image (D) and merged (E) (Bar  100 M).
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studies showed that the transfection efficiency was strongly
dependent on the cell cycle stage at the time of transfection, and the
higher transfection efficiency appeared during S or G2/M phase. We
tried to verify whether the cell cycle dependence finding based on
the cell line studies from Professor Wagner’s group [31, 32] are
applicable to hMSCs as well. If all the donors were assumed from
one population for statistic analysis, no correlation between the
transfection efficiency and the cell percentage in S phase was found.
It seems that the cell cycle dependence is not applicable to hMSCs.
However, Pearson correlation analysis revealed that there were 
two subpopulations; in each subpopulation the transfection effi-
ciency was linearly related to the cell percentage in S phase. 
Non-parametric Mann-Whitney test further confirmed that the
transfection efficiencies in these two subpopulations were from two
different distributions, but the cell percentages in S phase were not.
We screened the immunophenotyping surface antigens of cells
from these two subpopulations by FACS analysis; however, we did
not observed significant differences in the cell surface antigens
between these two subpopulations. It is still not clear which internal
factors of donors lead to the two subpopulations. Further studies
are needed to investigate the correlation between the cell cycle and
the transfection efficiency in hMSCs.
© 2011 The Authors
Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd
Fig. 5 The effect of cell resource on transfection efficiency.  No correlation was observed between transfection efficiency and donors’ age according to
Spearman’s rank correlation analysis (A). Independent-samples t-test revealed there was no significant difference of transfection efficiency between mid-
dle-age (n  9) and old-age (n  21) groups (B), and between female (n  7) and male (n  23) groups (C). The result was expressed as average 
S.E.M. (standard error of the mean).
Fig. 6 Association between transfection efficiency and the cell percentage in S phase. Two subpopulations were found and linear regression indicated the
trend towards the correlation between transfection efficiency and the cell percentage in S phase in each subpopulation (A). A representative histogram of cell
cycle analysis via PI staining and FACS detection (B). Phenotypic characterization showed no significant difference between these two subpopulations (C)
[Average  S.E.M, n  4 (P1) and n  3 (P2)].
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The importance of this study is related to the clinical trials that
administrate human MSCs to the patients with ischemic 
cardiovascular diseases for regenerating cardiac functions. 
Age-related decline in cardiac and vascular regenerative capacity
of stem cells indicate that cardiac regeneration is a highly com-
plex process involving a series of coordinated key events includ-
ing cell homing, engraftment, survival, paracrine factor release
and differentiation that need to be exploited for cardiac repair and
functional recovery [33, 34]. Hence, genetic modification of stem
cell may be an important strategy with virus vectors in the
preclinical identification of genes responsible for the key events
in stem cell based cardiac regeneration. Indeed, genetic manipu-
lation of rat MSCs with Akt [18], heme oxygenase (HO)-1 [35]
and stromal cell-derived factor (SDF)-1 [36] by virus vectors have
induced an increase in stem cell survival within the infarct 
zone and shown improved cardiac function. As virus vector 
may not completely silence its encoded genes in cells, it may
induce malignant transformation of stem cells and immune
response after cell transplantation. Hence, it is indispensable to
deliver therapeutic genes into the MSCs with non-viral vector in
clinical application.
Although we got some transfections with relative high 
efficiency (15%), not all samples showed such high efficiency.
Among the 30 samples we tested, only 8 samples had efficiency
more than 5%, and only 2 had efficiency more than 10%. The
average transfection efficiency for all of samples was 4.32%.
Ozawa et al. implanted VEGF-transduced myoblasts into 
muscles of adult mice and found that a very low level of VEGF 
(~5 ng/106 cells/day) was able to yield homogeneous normal 
capillary-like vessels while aberrant vasculature was induced at
VEGF levels above 70 ng/106 cells/day [37]. Our data suggested
that PEI-mediated therapeutic gene VEGF transfer into hMSCs
could produce expression levels ranging from 35 ng/106 cells/day
to 230 ng/106 cells/day. This provides the probability of achieving
therapeutic efficacy by implanting modified cells with lower num-
ber than unmodified cells. Thus, the duration of ex vivo expansion
of hMSCs could be shortened, which could reduce the risk of
long-term culture such as spontaneous immortalization and
malignant transformation [38–42].
However, the transfection efficiency still needs to be
enhanced to improve therapeutic efficacy by transplantation of
non-viral vector modified hMSCs. It may be critical to develop
nuclear targeting strategies for hMSCs transfection. Hence,
intracellular trafficking of PEI/DNA complexes is highly valued to
elucidate the cellular mechanism of non-viral vector mediated
transfection in hMSCs.
Conclusion
In summary, the optimization of PEI mediated gene delivery into
hMSCs derived from patients has been carried out. The transfec-
tion efficiency did not show any correlation either with the age or
the gender of the donors. Statistically, there were two subpopula-
tions in the patients; and transfection efficiency in each subpopu-
lation was linearly related to the cell percentage in S phase. No
significant phenotypic differences were observed between these
two subpopulations. Furthermore, PEI-mediated therapeutic gene
VEGF transfer could significantly enhance the expression level.
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